Emily Bodnar, an analyst at H.C. Wainwright, raised her price target for Purple Biotech Ltd. (NASDAQ:PPBT) from $33 to $34 ...

As the White House moves to revoke Harvard University’s certification to enroll foreign students — escalating a battle ...

Take a closer look at London's biotech hub – renowned for its thriving life sciences ecosystem and world-class infrastructure ...

The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.

A US-based biotech company has successfully sequenced the genetic codes of preserved plants, some of which date back more ...

Castle Biosciences, Inc. (NASDAQ:CSTL)’s Dx-Melanoma test, which evaluates a 31-gene expression profile, offers significant, ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking ...

Yes, PCRX’s Q1 was not pretty, miserable 1% sales growth rate and collapse of operating profit from last year’s Q1. But, hey, ...

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

Naples-headquartered biotechnology company Enveric Biosciences announced positive preclinical results for its lead drug candidate, EB-003, in a severe depression mouse model.